Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike protein, Nucleocapsid protein, and conserved T-cell epitopes (SARS-CoV-2 S/N/T-cell epitopes)

The target SARS-CoV-2 Spike, Nucleocapsid, and conserved T cell epitope regions represents a composite antigenic profile used in next-generation COVID-19 vaccines to elicit a broad and durable immune response. The Spike (S) protein is the primary surface glycoprotein of SARS-CoV-2, responsible for binding to the host ACE2 receptor and mediating viral entry, making it the primary target for neutralizing antibodies [5, 13]. The Nucleocapsid (N) protein is a highly conserved internal structural protein that packages the viral RNA genome and serves as a major target for T-cell mediated immunity [5, 11]. Conserved T-cell epitope regions are specific peptide sequences within these and other viral proteins that are less prone to mutation across variants, ensuring that cellular immunity remains effective even as the virus evolves [1, 7]. By combining these elements, therapeutic candidates like UB-612 and GRT-R910 aim to overcome the limitations of Spike-only vaccines, which are more susceptible to immune evasion by variants of concern [4, 10, 19]. This multi-antigen approach is designed to stimulate both high-titer neutralizing antibodies and robust CD4+ and CD8+ T-cell responses for long-term protection [2, 6, 14].

Other names

SARS-CoV-2 multi-antigen targetSARS-CoV-2 S+N+T-cell epitopesCOVID-19 multi-epitope antigenSARS-CoV-2 S/N/M multitope

Induction of neutralizing antibodies against the Spike protein to block viral entry and activation of CD4+ and CD8+ T-cells against Nucleocapsid and conserved epitopes to clear infected cells and provide long-term immunity.